Impact Factor: 9.2 ISSN-L: 2544-980X

Correction of the Hemostatic Potential of the Blood in Conditions of Hemodilution and Acidosis in Patients With Acute Leukemia

Abdiyev Kattabek Makhmatovich [1], Asomiddinova Shaxnoza Kamolovna [2], Abidova Xulkar Shuxrat kizi [3]

Abstract: Hemostatic problems brought on by coagulopathy and thrombocytopenia are common in patients with acute leukemia. Coagulopathy can result in considerable morbidity and death and makes patient treatment more difficult. The purpose of this guidance document is to review and offer recommendations regarding the management of hemostatic complications in adult patients with acute leukemia. It addresses four primary concerns: the use of antifibrinolytic agents; platelet transfusion; disseminated intravascular coagulation; and hypofibrinogenemia related to L-asparaginase.

Keywords: patient, hemostatic complications, blood, cure, diagnosis, treatment, medication.

INTRODUCTION

Anti-neoplastic medication, coagulopathy from the underlying illness, and possible consequences (like sepsis) that increase morbidity and mortality are some of the causes that typically cause thrombocytopenia and hemostatic problems in patients with acute leukemia. In order to provide clinical guidance on the management of hemostatic complications in patients with acute leukemia, two Scientific and Standardization Committees (SSC) of the International Society on Thrombosis and Haemostasis (ISTH) collaborated to create this guidance document: the Perioperative & Critical Care Thrombosis and Hemostasis Subcommittee and the Hemostasis & Malignancy Subcommittee. Recommendations are robust guiding statements backed by excellent clinical trial evidence. Recommendations are based on expert opinion or low-quality evidence, and they reflect weaker advice statements. Considering how complicated coagulopathy is in this particular group. This study will concentrate on four primary concerns about hemostatic consequences in adult acute leukemia patients: platelet transfusion, antifibrinolytic medication usage, L-asparaginase-related hypofibrinogenemia, and disseminated intravascular coagulation (DIC). Based on the writers' collective viewpoint, guiding statements for each of the issues were created after a review of the existing literature. Previous SSC advice publications have addressed thrombotic problems related to acute leukemia, such as managing thrombosis in cancer patients with thrombocytopenia [1. 54p] and those related to L-asparaginase [2].

MAIN PART

Definitions

Hemostatic inconveniences. The objective circumstances are procured confusions connected with hemostasis because of the fundamental intense leukemia or its therapy.

Intense leukemia. This direction archive incorporates reference to intense myeloid leukemia (AML) and intense lymphoblastic leukemia (ALL).

Hemostatic difficulties due to coagulopathy is one of the main sources of mortality in patients with intense leukemia [3]. Routine coagulation tests might uncover DIC with prolongation of prothrombin time (PT), variable enacted halfway thromboplastin time (aPTT), low fibrinogen levels and platelet

[1] Associate Professor of the Department of Hematology Samarkand State Medical University
[2] Student of group 401 of the Faculty of Medical Biology Samarkand State Medical University
[3] Student of group 401 of the Faculty of Medical Biology Samarkand State Medical University

counts, and raised D-dimer and fibrin-corruption items. Larger part of patients with intense promyelocytic leukemia (APL) (70-80%) foster DIC over the span of finding and therapy. Albeit current APL helpful regimens consolidating all-trans retinoic corrosive (ATRA) or arsenic trioxide (ATO) are related with high probability of long haul abatement and infection free endurance, discharge stays the most widely recognized reason for death during enlistment treatment [3. 34p]. Essentially, DIC has been accounted for in 10-20% of non-APL intense leukemia on finding, with a much higher gamble (60-70%) after the commencement of acceptance chemotherapy. This direction record tends to the administration of hemostatic confusions in grown-up patients with intense leukemia, enveloping issues connected with platelet bonding, DIC, L-asparaginase-related hypofibrinogenemia, and the utilization of antifibrinolytic specialists.

Platelet transfusion

Thrombocytopenia is normal in patients with intense leukemia. A few randomized preliminaries in patients with hematologic harm or chemotherapy-related thrombocytopenia have laid out that extreme draining occasions were not any more regular in patients bonded prophylactically for a platelet count <10 × 109/L contrasted and <20 or 30 × 109/L [1. 4-7p]. Prophylactic platelet bonding for a platelet count <10 × 109/L delayed the chance to the 1st grade 2 or higher drain (as characterized by World Wellbeing Association) and diminished the quantity of long stretches of discharge when contrasted with remedial platelet bonding (bonding just for side effects). By and by, a decrease in draining gamble was not related with an endurance benefit [3. 89p]. Besides, an advantage from prophylactic platelet bonding isn't obvious in patients going through autologous undeveloped cell relocate [2. 10p], and the portion of platelet bonding doesn't seem to influence draining results [5. 11p].

As patients with leukemia often get platelet bondings, platelet hard-headedness, characterized as the failure to create a palatable augmentation in the post-bonding platelet count, is normal and testing to make due. Etiologies for platelet recalcitrance incorporate non-insusceptible factors frequently because of expanded utilization that record for more than 80% of the cases (e.g., splenomegaly, dying, fever, contamination, DIC, and prescriptions) [1. 23p], and invulnerable related factors (e.g., alloimmunization). In patients unmanageable to platelet bonding, a methodology of remedial platelet bonding for draining and prophylactic bonding for periprocedural the executives might be more proper. Little proof recommends an advantage from ceaseless platelet implantation, intravenous immunoglobulin, splenectomy, or plasma trade [1. 35p].

Among the minority of patients in whom clinical variables are deficient to clear up stubbornness for platelet bonding, the essential resistant reason is alloimmunization to human leukocyte antigens (HLA). Alloimmunization results from past pregnancy, blood bonding, or organ transplantation. As platelets express just class I HLA-A and HLA-B, alloantibodies to these antigens are most generally embroiled in alloimmune recalcitrance. The Preliminary to Decrease Alloimmunization to Platelets (TRAP) showed the viability of leukoreduction in diminishing both the gamble of alloimmunization and the improvement of platelet recalcitrance in patients with AML getting enlistment chemotherapy [1.41p]. Among patients who are HLA-alloimmunized, three methodologies can be utilized to track down prevalent viable platelet items: 1) platelet crossmatching [1. 51p]; 2) HLA matching [1. 69p]; and 3) HLA aversion [1. 71p]. Platelet crossmatching includes hatching patients' serum with contributor platelets to survey similarity. HLA matching includes matching class I HLA-A and B antigens between the giver and patient. HLA evasion requires the ID of the HLA alloantibodies made by the patient. The platelet items are then chosen in light of the shortfall of antigens to which the patient has recognized antibodies. The ideal technique ought to be chosen after discussion with neighborhood bonding offices.

Scattered intravascular coagulopathy (DIC)

Definition and models

DIC is described by foundational intravascular enactment of the coagulation framework from different causes that can result in multiorgan disappointment, apoplexy, and additionally unreasonable dying. The finding of DIC is trying because of the complex basic ailments of leukemia that can prompt

variable introductions. Three principal demonstrative scores have been proposed, doling out 0-3 focuses to various degrees of research center outcomes, including platelet count, fibrin-related markers, fibrinogen, and prothrombin time (PT) [4. 18-20p]. A planned report showed no massive contrasts in the prognostic results of DIC among these three scoring frameworks [2. 21p]. Be that as it may, in intense leukemia, thrombocytopenia is exceptionally pervasive because of bone marrow contribution by the illness or chemotherapy. The Japanese Service of Wellbeing and Government assistance (JMHW) altered rules for extreme thrombocytopenia, which rejected platelet count or draining side effects, showed unrivaled awareness and negative prescient qualities than the ISTH standards in the finding of intense leukemia-related DIC in one review [2. 24p]. All the more as of late, one more scoring framework, the Chinese Society of Apoplexy and Hemostasis scoring framework for DIC (CDSS) were proposed and approved tentatively in patients with and without hematological danger and found to have ideal symptomatic and prognostic utility, however it has not been broadly used [2. 32p].

Occurrence and chance factors

The frequency of DIC differs generally in distributed examinations, in spite of the fact that APL has the most elevated risk with a detailed rate of 70-80%. Most of the investigations were little, single-focus and review, and frequently without a normalized convention for assessment of DIC. Different DIC models were used, and various sorts of leukemia were incorporated, bringing about a profoundly factor rate of DIC. As a general rule, the occurrence of DIC was higher in patients with AML (when contrasted with ALL) and during enlistment treatment. Patients with DIC had more hemorrhagic or thrombotic intricacies when contrasted with those without DIC and unmistakable DIC by ISTH models was demonstrated to be serious areas of strength for of apoplexy however not significant drain [3. 45p].

APL is related with an especially high gamble of hemorrhagic difficulties, no matter what the presence of DIC, and draining remaining parts to be the primary driver of early mortality [3. 75p]. The fundamental treatment objective in this populace has been to decrease early mortality. A few review concentrates on researched the frequency and chance elements for extreme discharge or hemorrhagic passing [3, 38-48]. The hemorrhagic passing rate shifted from 5 to 20%, with an extreme draining pace of 30%. Intracranial draining was the reason for hemorrhagic passing in a high level of patients. The most widely recognized risk factors for drain incorporated a high white platelet count, impact count, or coagulopathy.

The executives

The pillar in the administration of DIC is the treatment of the basic sickness. In patients with intense leukemia, antineoplastic treatment is much of the time joined by a fast goal of DIC. This is ordinarily the situation with APL, where DIC normally subsides in the span of multi week following ATRA commencement [49]. Beneath we explored other treatment choices for DIC in patients with intense leukemia.

CONCLUSION

Given the high gamble of drain, especially in the setting of thrombocytopenia in patients with intense leukemia, antifibrinolytic specialists, for example, aminocaproic corrosive or tranexamic corrosive have been explored as an adjunctive therapy methodology. In huge randomized preliminaries, antifibrinolytic specialists fundamentally diminished discharge related mortality in post pregnancy and injury patients and decreased draining in careful patients, without an expanded gamble of apoplexy [5. 44p]. Nonetheless, proof supporting the utilization of antifibrinolytic specialists in intense leukemia patients stays restricted and is generally founded on single-focus review studies and pre-1990 little randomized preliminaries [3, 61-70p]. Most examinations were little, single-arm studies without a benchmark group, utilizing different dosing methodologies, and with exceptionally factor result detailing. The GIMEMA and PETHEMA studies both didn't exhibit a helpful advantage of antifibrinolytic specialists to diminish hemorrhagic mortality in patients with APL [3. 71p]. A 2016

Cochrane meta-examination presume that the accessible proof of utilizing antifibrinolytic specialists in patients with hematological sicknesses is restricted and further examinations are required [6. 87p].

REFERENCES:

1. Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2018; 16: 1246–9. 10.1111/jth.14015.
2. Zwicker JI, Wang TF, DeAngelo DJ, Lauw MN, Connors JM, Falanga A, McMasters M, Carrier M. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. *J Thromb Haemost*. 2020; 18: 278–84. 10.1111/jth.14671.
3. de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, Esteve J, Bergua JM, Milone G, Deben G, Rivas C, Gonzalez M, Tormo M, Diaz-Mediavilla J, Gonzalez JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. *Blood*. 2008; 111: 3395–402. 10.1182/blood-2007-07-100669.
4. Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. *Cancer*. 2006; 107: 136–40. 10.1002/cncr.21958.
5. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. *Blood*. 1990; 75: 2112–7.
6. Estcourt LJ, Desborough M, Brunskill SJ, Doree C, Hopewell S, Murphy MF, Stanworth SJ. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. *Cochrane Database Syst Rev*. 2016; 3: CD009733. 10.1002/14651858.CD009733.pub3.
7. Ibatova, S. M., & Mamatkulova, F. K. (2023). SOME FEATURES OF HEMOCOAGULATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. *Academia Science Repository*, *4*(6), 89-96.
8. Ibatova, S. M., Mamatkulova, F. K., & Ruzikulov, N. Y. (2020). The clinical picture of acute obstructive bronchitis in children and the rationale for immunomodulatory therapy. *International Journal of Current Research and Review*, *12*(17), 152-155.